Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
NEW YORK, NY / ACCESSWIRE / December 23, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca
SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of AstraZeneca PLC (NASDAQ: AZN) publicly traded securities between February 23, 20
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of AstraZeneca PLC Investors – AZN
03:19pm, Monday, 23'rd Dec 2024
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) betwe
AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC
12:02pm, Monday, 23'rd Dec 2024
AstraZeneca wins approval in the EU for the label expansion of Tagrisso to treat adult patients with locally advanced, unresectable NSCLC.
AstraZenca's Tagrisso approved in Europe for rare lung cancer
03:02am, Monday, 23'rd Dec 2024
AstraZeneca PLC's (LSE:AZN) Tagrisso has been approved in Europe for treating adults with non-small cell lung cancer (NSCLC) that cannot be removed by surgery. The approval is for patients whose tum
4 Ideal Buys From 15 'Safer' Dividends On Bloomberg's 50 December 2025 Watchlist
05:48am, Sunday, 22'nd Dec 2024
Bloomberg Intelligence analysts identified 50 watchable companies for 2025, focusing on potential catalysts like new leadership and geopolitical impacts, with 37 paying dividends. Fourteen of these di
Is AstraZeneca Stock a Buy?
05:45am, Sunday, 22'nd Dec 2024
U.K.-based pharmaceutical giant AstraZeneca (AZN 1.41%) is making news, but not in a good way. Its operations in China were recently rocked when Leon Wang, the company's president in the country -- as
AZN STOCK ALERT: Levi & Korsinsky Notifies AstraZeneca PLC Investors of an Ongoing Investigation
06:01pm, Saturday, 21'st Dec 2024
NEW YORK, NY / ACCESSWIRE / December 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible viola
Why Astrazeneca (AZN) Outpaced the Stock Market Today
07:16pm, Friday, 20'th Dec 2024
Astrazeneca (AZN) closed at $65.35 in the latest trading session, marking a +1.41% move from the prior day.
NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible viola
AZN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by AstraZeneca PLC
02:00pm, Thursday, 19'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible viola
AstraZeneca (AZN) Shares Fall After Reports of PRC Probe Alleged Fraud and Corruption – Hagens Berman
01:24pm, Thursday, 19'th Dec 2024
SAN FRANCISCO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- AstraZeneca PLC (NASDAQ: AZN) is facing a significant crisis in China as authorities there investigate the company for alleged fraud, illegal drug impo
AstraZeneca Digital Transformation Strategy Profile 2024 - Accelerators, Incubators and Innovation Programs
05:18am, Thursday, 19'th Dec 2024
Dublin, Dec. 19, 2024 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: AstraZeneca Plc 2024" company profile has been added to ResearchAndMarkets.com's offering.
AstraZeneca PLC (AZN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
07:45pm, Wednesday, 18'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible viola
NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of AstraZeneca P
